First regimen to be approved in India to demonstrate superiority to platinum-containing chemotherapy, the current standard of care for adult patients with unresectable or metastatic urothelial cancer for nearly 40 years. The Central Drugs Standard Control Organization approval was based on the global Phase 3 EV-302 trial (also known as KEYNOTE-A39) where the combination treatment nearly doubled median overall survival and significantly extended progression free survival outcomes1 (Brand Connect Initiative)